InvestorsHub Logo
Followers 3
Posts 277
Boards Moderated 0
Alias Born 12/21/2022

Re: Gogh9 post# 3255

Saturday, 04/29/2023 1:48:11 PM

Saturday, April 29, 2023 1:48:11 PM

Post# of 3283
Yes, not a bad deal. With only one drug, competing with multiple biosimilars in rapidly shrinking long acting G-CSF market, Spectrum would have a bleak future. After Poziotinib rejection, buyout or merger were right things to do.
I am reading more about Indocin. Not sure I like this quote, "In 2008, a box of 30 anti-inflammatory rectal suppositories that treats arthritis, called Indocin, had a price tag of $198. As of Oct. 1, 2021, the price of that same box was 52 times higher, totaling $10,350".